uniQure (NASDAQ:QURE) Director Robert Gut Sells 7,552 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 7,552 shares of the company’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $26.05, for a total value of $196,729.60. Following the sale, the director owned 27,435 shares in the company, valued at approximately $714,681.75. This trade represents a 21.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Thursday, June 11th, Robert Gut sold 2,726 shares of uniQure stock. The stock was sold at an average price of $27.06, for a total value of $73,765.56.

uniQure Price Performance

Shares of NASDAQ QURE opened at $27.57 on Friday. The stock’s 50-day moving average is $22.52 and its two-hundred day moving average is $21.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The company had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. Analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the topic of several recent research reports. Cantor Fitzgerald restated a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Wells Fargo & Company upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a report on Monday, March 9th. Sanford C. Bernstein downgraded uniQure to a “market perform” rating in a report on Tuesday, March 3rd. TD Cowen reiterated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Chardan Capital increased their price objective on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, uniQure presently has an average rating of “Moderate Buy” and an average target price of $42.83.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in QURE. State Street Corp increased its holdings in shares of uniQure by 123.8% in the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. Orbimed Advisors LLC boosted its position in shares of uniQure by 189.7% in the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the period. Finally, MPM Bioimpact LLC purchased a new position in uniQure during the 4th quarter worth approximately $33,062,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.